All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Lipidated peptides as anti-obesity agents

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F18%3A00499641" target="_blank" >RIV/61388963:_____/18:00499641 - isvavai.cz</a>

  • Result on the web

    <a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20180410&DB=&locale=en_EP&CC=US&NR=9937235B2&KC=B2&ND=4#" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20180410&DB=&locale=en_EP&CC=US&NR=9937235B2&KC=B2&ND=4#</a>

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Lipidated peptides as anti-obesity agents

  • Original language description

    Lipidated peptides, analogs of both forms of the prolactin-releasing peptide, PrRP31 and PrRP20, represent anorexigenic compounds that lower food intake and function in the brain after peripheral administration. The analogs PrRP31 and PrRP20 lipidated at the N-terminus by myristic or palmitic acids bind with high affinity to the endogenous receptor GPR10 in the rat pituitary cell line RC-4B/C and CHO cell line with transfected human receptor. These lipidated peptides also significantly decrease, in a dose-dependent manner, the food intake in fasted mice and have similar effects in comparable doses as centrally administered natural PrRP31, these effects are, however, stronger and longer lasting. Lipidation of an effective anorexigenic neuropeptide PrRP induces a central effect after peripheral administration and thus makes the lipidated analogs of PrRP a promising anti-obesity drug.

  • Czech name

  • Czech description

Classification

  • Type

    P - Patent

  • CEP classification

  • OECD FORD branch

    30104 - Pharmacology and pharmacy

Result continuities

  • Project

    <a href="/en/project/TE01020028" target="_blank" >TE01020028: Center for Development of Original Drugs</a><br>

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2018

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Patent/design ID

    US9937235

  • Publisher

    US001 -

  • Publisher name

    United States Patent and Trademark Office (USPTO)

  • Place of publication

    Alexandria

  • Publication country

    US - UNITED STATES

  • Date of acceptance

    Apr 10, 2018

  • Owner name

    Ústav organické chemie a biochemie AV ČR, v. v. i

  • Method of use

    B - Výsledek je využíván orgány státní nebo veřejné správy

  • Usage type

    A - K využití výsledku jiným subjektem je vždy nutné nabytí licence